Picture EBD Group BIO-Europe Spring 2021 Digital 650x80

Organisation › Details

CureVac N.V. (Nasdaq: CVAC)

	Start	2020-08-10 existent
	Predecessor	CureVac AG
	Industry	mRNA technology
	Industry 2	mRNA-based drug
	Person	Haas, Franz-Werner (CureVac 202008– CEO joined 201206 as COO before Sygnis + Lion BIoscience)
	Person 2	Hoerr, Ingmar (CureVac 201806– Chairman of Supervisory Board before 2000–201806 CEO + Co-Founder)

	Region	Netherlands_oo
	Country	Netherlands
	City	n. a.
		Address record changed: 2020-08-12

Basic data	Employees	n. a.


		Record changed: 2021-02-20

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for CureVac N.V. (Nasdaq: CVAC)

[1] CureVac N.V.. (2/12/21). "Press Release: CureVac Initiates Rolling Submission with European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV". Tübingen & Boston, MA....
[2] GlaxoSmithKline plc. (2/3/21). "Press Release: GSK and CureVac to Develop Next Generation mRNA COVID-19 Vaccines". London, Tübingen & Boston, MA....
[3] CureVac N.V.. (1/28/21). "Press Release: CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares". Tübingen & Boston, MA....
[4] CureVac N.V.. (1/25/21). "Press Release: CureVac Announces Proposed Public Offering of Common Shares". Tübingen & Boston, MA....
[5] CureVac N.V.. (1/7/21). "Press Release: CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV". Berlin, Tübingen & Boston; MA....
[6] CureVac N.V.. (12/23/20). Web Site: Leadership – Executive Board, Supervisory Board and Scientific Advisory Board. [https://www.curevac.com, 12/23/20]...
[7] CureVac N.V.. (12/9/20). "Press Release: CureVac and Fareva Sign Agreement for Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV". Tübingen & Boston, MA....
[8] CureVac N.V.. (12/4/20). "Press Release: CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer". Tübingen & Boston, MA....
[9] Kaleido Biosciences, Inc.. (10/1/20). "Press Release: Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer". Lexington, MA....
[10] CureVac N.V.. (9/29/20). "Press Release: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate. Study Conducted in Peru and Panama". Tübingen & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]